Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group-Reference-Cited by-同舟云学术

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group

Published:2022-10 Issue: Volume:365 Page:8-18
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Janez Andrej,Muzurovic Emir,Stoian Anca Pantea,Haluzik Martin,Guja Cristian,Czupryniak Leszek,Duvnjak Lea,Lalic Nebojsa,Tankova Tsvetalina,Bogdanski Pawel,Papanas Nikolaos,Nunes Josè Silva,Kempler Peter,Fras Zlatko,Rizzo Manfredi

Funder

Novo Nordisk

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference55 articles.

1. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons;Dalsgaard;Diabetes Obes. Metab.,2018

2. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus;Meier;Nat. Rev. Endocrinol.,2012

3. Updates on cardiovascular outcome trials in diabetes;Schnell;Cardiovasc. Diabetol.,2017

4. Incretin-based therapies in 2021 - current status and perspectives for the future;Rizzo;Metabolism.,2021

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence;Current Pharmaceutical Design;2024-08

2. Maturity-onset diabetes of the young (MODY) - in search of ideal diagnostic criteria and precise treatment;Progress in Cardiovascular Diseases;2024-07

3. Non-pharmacological interventions to improve cardiovascular risk factors in people with diabetic foot disease: A systematic review and meta-analysis;Diabetes Research and Clinical Practice;2024-03

4. GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?;Journal of Diabetes and its Complications;2023-12

5. Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus;Journal of Diabetes and its Complications;2023-12